We bring you the latest news from the healthcare about the health care in the United Kingdom.

maandag 2 juli 2018

Gene Therapy - Table of Contents alert Volume 25 Issue 3

If you are unable to see the message below, click here to view.
Gene Therapy

NATURE FEATURE: Growing Pains for Gene Therapy Manufacturing 

The first of a four-part series highlighting new gene therapy production strategies and technologies. The first installment discusses the progress that has been made as the first wave of gene therapies win market approval and the challenges that must be overcome to relieve the production bottleneck when manufacturing cutting edge gene therapies at scale. 

Read feature here

Volume 25, Issue 3

In this issue
Review Article
Brief Communication
Also new
  • High Titer > 10e13-14 GC/ml
  • Research-grade and clinical viral vector production
  • Delivered in 2 weeks

Learn more about AAV services 

The event will be led by scientists and clinicians researching, developing and testing new treatments for genetically inherited and acquired diseases, using gene delivery technology, stem cell manipulation and DNA repair techniques, covering aspects including: scientific principles, molecular basis of disease, current and developing technologies and clinical applications.

More info 


CAR-T in the clinic: drive with care

Rafael J. Yáñez-Muñoz & Stephan A. Grupp

Gene Therapy 2018 25 :157 - 161; July 01, 2018; 10.1038/s41434-018-0023-x


Abstract | Full Text


The revving up of CARs

Muhammad Bilal Abid

Gene Therapy 2018 25 :162 - 162; April 13, 2018; 10.1038/s41434-018-0015-x


Abstract | Full Text

CAR-T: trailblazing the path from clinical development to the clinic

Samuele Butera

Gene Therapy 2018 25 :163 - 164; April 23, 2018; 10.1038/s41434-018-0013-z


Abstract | Full Text

Driving cars to the clinic for solid tumors

Mauro Castellarin, Keisuke Watanabe, Carl H. June, Christopher C. Kloss & Avery D. Posey Jr.

Gene Therapy 2018 25 :165 - 175; June 07, 2018; 10.1038/s41434-018-0007-x


Abstract | Full Text

Fludarabine and neurotoxicity in engineered T-cell therapy

Kate L. Lowe, Crystal L. Mackall, Elliot Norry, Rafael Amado, Bent K. Jakobsen et al.

Gene Therapy 2018 25 :176 - 191; May 07, 2018; 10.1038/s41434-018-0019-6


Abstract | Full Text

Review Article

Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy

Y Huang, D Li, D-Y Qin, H-F Gou, W Wei et al.

Gene Therapy 2017 25 :192 - 197; September 21, 2017; 10.1038/gt.2017.81


Abstract | Full Text


Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy

Wen-ying Zhang, Yang Liu, Yao Wang, Jing Nie, Ye-lei Guo et al.

Gene Therapy 2018 25 :198 - 204; March 29, 2018; 10.1038/s41434-017-0001-8


Abstract | Full Text

Brief Communication

Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain

Jennifer A. Sullivan, Lisa M. Stanek, Michael J. Lukason, Jie Bu, Shayla R. Osmond et al.

Gene Therapy 2018 25 :205 - 219; May 22, 2018; 10.1038/s41434-018-0017-8


Abstract | Full Text

In vivo selection with lentiviral expression of Bcl2T69A/S70A/S87A mutant in hematopoietic stem cell-transplanted mice

Yan-Yi Wang, Shan Ma, Qingyong Chen, Demin Jiao & Yong Yang

Gene Therapy 2018 25 :220 - 233; March 09, 2018; 10.1038/s41434-018-0008-9


Abstract | Full Text

Effects of microRNA-292-5p on myocardial ischemia–reperfusion injury through the peroxisome proliferator-activated receptor-α/-γ signaling pathway

Zhen-Dong Zhu, Ji-Yun Ye, Hua Niu, Yu-Mei Ma, Xue-Mei Fu et al.

Gene Therapy 2018 25 :234 - 248; April 18, 2018; 10.1038/s41434-018-0014-y


Abstract | Full Text

Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Gene Therapy.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature